Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Evotec AG    EVT   DE0005664809

EVOTEC AG (EVT)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Most relevant news about EVOTEC AG
06/21EVOTEC : and Sanofi sign definitive agreement to combat infectious diseases
AQ
06/20EVOTEC : Resolutions of the annual general meeting 2018 of evotec ag
EQ
06/18Evotec Shares Jump After It Secures Sanofi Agreement
DJ
06/18EVOTEC : And sanofi sign definitive agreement to combat infectious diseases
EQ
06/01EVOTEC : forms academic BRIDGE LAB591 with Arix Bioscience and Fred Hutchinson C..
AQ
06/01ARIX BIOSCIENCE : Evotec, Fred Hutch in research deal
AQ
05/31EVOTEC : and Celgene expand iPSC collaboration to include additional cell lines
AQ
05/31EVOTEC : Forms Academic Bridge 'LAB591' with Arix Bioscience and Fred Hutchinson..
BU
05/31EVOTEC : Forms academic bridge 'lab591' with arix bioscience and fred hutchinson..
EQ
05/29EVOTEC : and Celgene Expand IPSC Collaboration to Include Additional Cell Lines
BU
05/29EVOTEC : And celgene expand ipsc collaboration to include additional cell lines
EQ
05/24EVOTEC : expands iPSC platform with licence from ID Pharma
AQ
05/22EVOTEC : and Celgene Enter into Strategic Oncology Partnership
BU
05/21EVOTEC : And celgene enter into strategic oncology partnership
EQ
05/21EVOTEC : and Celgene enter into strategic oncology partnership
EQ
More most relevant news
All news about EVOTEC AG
06/21EVOTEC : and Sanofi sign definitive agreement to combat infectious diseases
AQ
06/20EVOTEC : Resolutions of the annual general meeting 2018 of evotec ag
EQ
06/19EVOTEC : and Sanofi Sign Definitive Agreement to Combat Infectious Diseases
AQ
06/19SANOFI : Evotec says Sanofi deal makes it anti-infectives powerhouse
AQ
06/18Evotec Shares Jump After It Secures Sanofi Agreement
DJ
06/18EVOTEC AG : Evotec And Sanofi Sign Definitive Agreement To Combat Infectious Dis..
AC
06/18EVOTEC : And sanofi sign definitive agreement to combat infectious diseases
EQ
06/07EVOTEC : Forms Academic Bridge 'LAB591' with Arix Bioscience and Fred Hutchinson..
AQ
06/07EVOTEC : and Celgene Expand IPSC Collaboration to Include Additional Cell Lines
AQ
06/01EVOTEC : forms academic BRIDGE LAB591 with Arix Bioscience and Fred Hutchinson C..
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
06/20Roche to Buy Rest of Cancer Firm -- WSJ
DJ
06/20Latecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19Alexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/19Roche to Pay $2.4 Billion for Full Control of Foundation Medicine -- 2nd Upda..
DJ
06/19Roche pays $2.4 billion for rest of cancer expert Foundation Medicine
RE
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
05/31Evotec forms LAB591 with Arix Bioscience and Fred Hutchinson Cancer Research .. 
05/21Celgene teams up with Evotec to discover new cancer treatments 
05/09Evotec's (EVOTF) CEO Werner Lanthaler on Q1 2018 Results - Earnings Call Tran.. 
05/09Evotec AG 2018 Q1 - Results - Earnings Call Slides 
05/09Evotec AG reports Q1 results 
04/11Petra Pharma teams up with Evotec to develop lead candidate Petra-01 
Latest Tweets
06/20RESOLUTIONS OF THE ANNUAL GENERAL MEETING 2018 OF EVOTEC AG  
06/19Sanofi transfers infectious disease unit to Evotec
1
06/18Evotec seals deal for Sanofi’s infectious disease unit: Evotec has wrapped up..
1
06/18Evotec seals deal for Sanofi’s infectious disease unit  
06/18EVOTEC AND SANOFI SIGN DEFINITIVE AGREEMENT TO COMBAT INFECTIOUS DISEASES
1
More tweets
Qtime:35
Financials (€)
Sales 2018 351 M
EBIT 2018 46,1 M
Net income 2018 34,2 M
Debt 2018 70,3 M
Yield 2018 -
P/E ratio 2018 63,23
P/E ratio 2019 44,49
EV / Sales 2018 6,54x
EV / Sales 2019 5,96x
Capitalization 2 225 M
Chart EVOTEC AG
Duration : Period :
Evotec AG Technical Analysis Chart | EVT | DE0005664809 | 4-Traders
Technical analysis trends EVOTEC AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 19,9 €
Spread / Average Target 34%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Mario Polywka Chief Operating Officer
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC AG11.70%2 587
CELLTRION, INC.--.--%33 064
IQVIA HOLDINGS INC6.98%21 789
LONZA GROUP2.35%20 356
INCYTE CORPORATION-22.94%15 565
ALNYLAM PHARMACEUTICALS, INC.-17.65%10 581